塞德斯医疗(CLDX)
icon
搜索文档
Celldex Therapeutics(CLDX) - 2020 Q1 - Quarterly Report
2020-05-07 04:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 CLDX Nasdaq Capital Market FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (E ...
Celldex Therapeutics(CLDX) - 2019 Q4 - Annual Report
2020-03-27 04:09
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 | --- | --- | |--------------------------------------------------------------- ...
Celldex Therapeutics(CLDX) - 2019 Q3 - Quarterly Report
2019-11-12 22:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware No. 13-3191702 (State or other jurisdiction of incorp ...
Celldex Therapeutics(CLDX) - 2019 Q2 - Earnings Call Transcript
2019-08-08 13:13
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Q2 2019 Results Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Sarah Cavanaugh - Senior Vice President, Corporate Affairs and Administration Anthony Marucci - Founder, President and Chief Executive Officer Margo Heath-Chiozzi - Senior Vice President, Regulatory Affairs Sam Martin - Senior Vice President and Chief Financial Officer Tibor Keler - Founder, Executive Vice President and Chief Scientific Officer Conference Call Participants Joseph ...
Celldex Therapeutics(CLDX) - 2019 Q2 - Quarterly Report
2019-08-08 04:06
Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 CLDX Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THER ...
Celldex Therapeutics(CLDX) - 2019 Q1 - Quarterly Report
2019-05-08 04:31
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware No. 13-3191702 (State or other jurisdiction of incorporat ...
Celldex Therapeutics(CLDX) - 2018 Q4 - Earnings Call Transcript
2019-03-08 11:21
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Q4 2018 Results Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Sarah Cavanaugh - Senior Vice President, Corporate Affairs and Administration Anthony Marucci - Co-Founder, President, Chief Executive Officer Tibor Keler - Co-Founder, Executive Vice President, and Chief Scientific Officer Sam Martin - Senior Vice President and Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good day, ladies and gentle ...
Celldex Therapeutics(CLDX) - 2018 Q4 - Annual Report
2019-03-08 05:11
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 | --- | --- | |--------------------------------------------------------------- ...